WO1996002240A3 - Use of inhibitors of human s-cd23 - Google Patents

Use of inhibitors of human s-cd23 Download PDF

Info

Publication number
WO1996002240A3
WO1996002240A3 PCT/EP1995/002693 EP9502693W WO9602240A3 WO 1996002240 A3 WO1996002240 A3 WO 1996002240A3 EP 9502693 W EP9502693 W EP 9502693W WO 9602240 A3 WO9602240 A3 WO 9602240A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
human
collagenase
implicated
allergy
Prior art date
Application number
PCT/EP1995/002693
Other languages
French (fr)
Other versions
WO1996002240A2 (en
Inventor
Gary Christie
Beverley Jane Weston
Original Assignee
Smithkline Beecham Plc
Gary Christie
Beverley Jane Weston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Gary Christie, Beverley Jane Weston filed Critical Smithkline Beecham Plc
Priority to EP95943503A priority Critical patent/EP0769939A1/en
Priority to JP8504670A priority patent/JPH10502656A/en
Publication of WO1996002240A2 publication Critical patent/WO1996002240A2/en
Publication of WO1996002240A3 publication Critical patent/WO1996002240A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Inhibitors of matrix metalloproteases such as collagenase are capable of inhibiting the release of human soluble CD23 and are therefore useful in the treatment and prophylaxis of conditions in which an excess of s-CD23 is implicated, such as allergy and autoimmune disease.
PCT/EP1995/002693 1994-07-13 1995-07-07 Use of inhibitors of human s-cd23 WO1996002240A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95943503A EP0769939A1 (en) 1994-07-13 1995-07-07 Use of inhibitors of human s-cd23
JP8504670A JPH10502656A (en) 1994-07-13 1995-07-07 Use of inhibitors of human S-CD23

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414157A GB9414157D0 (en) 1994-07-13 1994-07-13 Medical use
GB9414157.9 1994-07-13

Publications (2)

Publication Number Publication Date
WO1996002240A2 WO1996002240A2 (en) 1996-02-01
WO1996002240A3 true WO1996002240A3 (en) 1997-02-13

Family

ID=10758281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002693 WO1996002240A2 (en) 1994-07-13 1995-07-07 Use of inhibitors of human s-cd23

Country Status (4)

Country Link
EP (1) EP0769939A1 (en)
JP (1) JPH10502656A (en)
GB (1) GB9414157D0 (en)
WO (1) WO1996002240A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9609794D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
GB9609795D0 (en) * 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
GB9813451D0 (en) 1998-06-22 1998-08-19 Smithkline Beecham Plc Novel compounds
AU4653199A (en) * 1998-07-17 2000-02-07 Daiichi Fine Chemical Co., Ltd. Novel remedies for allergic diseases
EP1101496A4 (en) * 1998-07-17 2001-12-12 Fuji Yakuhin Kogyo Kk Therapeutic agents for allergic diseases
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
JP2003523994A (en) * 2000-02-24 2003-08-12 スミスクライン ビーチャム パブリック リミテッド カンパニー New CD23 inhibitor
EP1142910A1 (en) * 2000-04-07 2001-10-10 Jürgen Prof. Dr. Frey Inhibitors for the formation of soluble human CD23

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005716A1 (en) * 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
WO1990005719A1 (en) * 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
WO1990011287A1 (en) * 1989-03-21 1990-10-04 The United States Of America, Represented By The Secretary, United States Department Of Commerce Matrix metalloproteinase inhibitor peptides
EP0447353A1 (en) * 1990-01-24 1991-09-18 Ciba-Geigy Ag A pharmaceutical preparation for the maturation of prothymocytes
WO1992005447A1 (en) * 1990-09-21 1992-04-02 The Salk Institute For Biological Studies FUNCTIONAL ANTAGONISM BETWEEN PROTO-ONCOPROTEIN c-JUN AND HORMONE RECEPTORS
WO1992016517A1 (en) * 1991-03-22 1992-10-01 Xenova Limited Pharmaceutical xanthone derivatives
KR930002833A (en) * 1991-07-08 1993-02-23 강석재 Device for checking break of electric circuit
WO1993018173A2 (en) * 1992-03-11 1993-09-16 Xenova Limited Cd4 binding agents and inhibitors of collagenase and protein kinase c
WO1993020047A1 (en) * 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
WO1994010990A1 (en) * 1992-11-13 1994-05-26 British Biotech Pharmaceuticals Limited Inhibition of tnf production
WO1994021625A1 (en) * 1993-03-16 1994-09-29 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors
WO1994024140A1 (en) * 1993-04-17 1994-10-27 British Bio-Technology Limited Hydroxamic acid derivatives
WO1995009841A1 (en) * 1993-10-07 1995-04-13 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as inhibitors of cytokine production
WO1995013289A1 (en) * 1993-11-10 1995-05-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
WO1995019961A1 (en) * 1994-01-22 1995-07-27 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1995019956A1 (en) * 1994-01-20 1995-07-27 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1995019957A1 (en) * 1994-01-21 1995-07-27 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005716A1 (en) * 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
WO1990005719A1 (en) * 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
WO1990011287A1 (en) * 1989-03-21 1990-10-04 The United States Of America, Represented By The Secretary, United States Department Of Commerce Matrix metalloproteinase inhibitor peptides
EP0447353A1 (en) * 1990-01-24 1991-09-18 Ciba-Geigy Ag A pharmaceutical preparation for the maturation of prothymocytes
WO1992005447A1 (en) * 1990-09-21 1992-04-02 The Salk Institute For Biological Studies FUNCTIONAL ANTAGONISM BETWEEN PROTO-ONCOPROTEIN c-JUN AND HORMONE RECEPTORS
WO1992016517A1 (en) * 1991-03-22 1992-10-01 Xenova Limited Pharmaceutical xanthone derivatives
KR930002833A (en) * 1991-07-08 1993-02-23 강석재 Device for checking break of electric circuit
WO1993018173A2 (en) * 1992-03-11 1993-09-16 Xenova Limited Cd4 binding agents and inhibitors of collagenase and protein kinase c
WO1993020047A1 (en) * 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
WO1994010990A1 (en) * 1992-11-13 1994-05-26 British Biotech Pharmaceuticals Limited Inhibition of tnf production
WO1994021625A1 (en) * 1993-03-16 1994-09-29 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors
WO1994024140A1 (en) * 1993-04-17 1994-10-27 British Bio-Technology Limited Hydroxamic acid derivatives
WO1995009841A1 (en) * 1993-10-07 1995-04-13 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as inhibitors of cytokine production
WO1995013289A1 (en) * 1993-11-10 1995-05-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
WO1995019956A1 (en) * 1994-01-20 1995-07-27 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1995019957A1 (en) * 1994-01-21 1995-07-27 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors
WO1995019961A1 (en) * 1994-01-22 1995-07-27 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A.K.HEWSON ET AL.: "Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790", INFLAMMATION RESEARCH, vol. 44, no. 8, pages 345 - 349 *
B.J.SUTTON ET AL.: "The human IgE network", NATURE, vol. 366, 2 December 1993 (1993-12-02), pages 421 - 428 *
DATABASE WPI Derwent World Patents Index; AN 93-375338 *
K.GIJBELS ET AL.: "Reversal of Experimental Autoimmune Encephalomyelitis with a Hydroxamate Inhibitor of Matrix Metalloproteases", J.CLIN.INVEST., vol. 94, no. 6, pages 2177 - 2182 *

Also Published As

Publication number Publication date
EP0769939A1 (en) 1997-05-02
JPH10502656A (en) 1998-03-10
WO1996002240A2 (en) 1996-02-01
GB9414157D0 (en) 1994-08-31

Similar Documents

Publication Publication Date Title
NZ335981A (en) Ketobenzamides as calpain inhibitors
MXPA04003668A (en) Type 4 phosphodiesterase inhibitors and uses thereof.
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
DE69526206T2 (en) USE OF INTERLEUKIN-12 FOR THE PREVENTION OF TRANSPLANT AGAINST RECEIVER DISEASE
MY137757A (en) Therapeutic treatment
AU2002323337A1 (en) Use of dppiv inhibitors as diuretic and anti-hypertensive agents
CY2006007I2 (en) USE OF CGMP-PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF IMPOTENCE
IL107897A0 (en) Pyrrolopyrimidines
AU2713600A (en) Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
FI894541A (en) AIDS PROTEASE INHIBITOR BASERADE PAO IN AIDS CEILINGS.
DE69115280D1 (en) INDOLDER DERIVATIVES THAT INHIBIT LEUKOTRIA BIOSYNTHESIS.
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
DK0755249T3 (en) Use of Maillard reaction inhibitor to treat amyloidosis-based disease
WO1996002240A3 (en) Use of inhibitors of human s-cd23
IL115733A0 (en) Binding agents and their use for therapeutic treatment
MXPA05012302A (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor.
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
PL367287A1 (en) Use of proteasome inhibitors to treat dry eye disorders
WO2000064422A3 (en) Novel treatment of neurotraumatic conditions with raf inhibitor
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes
ZA9711468B (en) New use of comt inhibitors
IL139144A0 (en) Mycobacterial inhibitors
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
ZA966698B (en) Use of PDE inhibitors in the treatment of urinary bladder diseases.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995943503

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 1995943503

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 776133

Date of ref document: 19970811

Kind code of ref document: A

Format of ref document f/p: F

WWR Wipo information: refused in national office

Ref document number: 1995943503

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995943503

Country of ref document: EP